share_log

BioCryst Pharmaceuticals Updated Its Agreement With Torii Pharmaceutica For ORLADEYO In Japan; BioCryst Japan K.K. Responsible For All Commercial Promotion Activities And Torii Will Be Responsible For Hereditary Angioedema Disease Awareness Activities

BioCryst Pharmaceuticals Updated Its Agreement With Torii Pharmaceutica For ORLADEYO In Japan; BioCryst Japan K.K. Responsible For All Commercial Promotion Activities And Torii Will Be Responsible For Hereditary Angioedema Disease Awareness Activities

BioCryst Pharmicals更新了與Torii Pharmacetica在日本的ORLADEYO協議;BioCryst Japan K.K. 負責所有商業促銷活動,Torii 將負責遺傳性血管性水腫疾病宣傳活動
Benzinga ·  2023/11/30 09:11
BioCryst Pharmicals更新了與Torii Pharmacetica在日本的ORLADEYO協議;BioCryst Japan K.K. 負責所有商業促銷活動,Torii 將負責遺傳性血管性水腫疾病宣傳活動
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論